A Phase I/II Study of Revlimid (lenalidomide) in Combination with Vidaza (azacitidine) in Patients with Advanced Myelodysplastic Syndrome (MDS) - BMF 5405. Homo sapiens

This single-arm study design has been selected to investigate the safety of combination therapy with Vidaza (azacitidine) and Revlimid (lenalidomide) in a population of 18 participants with advanced MDS for the Phase I portion, and 18 participants for the Phase II portion. The multi-center nature of the study should enhance the general applicability of the results. Participants with advanced MDS were chosen because it is expected that the combination of the two drugs will by myelosuppressive, which can be considered a necessary toxicity to effect improvements in PR and CR rates in this advanced population, akin to participants with AML. Finally, the combination was chosen to be studied because currently available therapies in this population, and their effectiveness, are limited, and single-agent Vidaza (azacitidine), while effective at delaying transformation to AML or death, is not curative. The doses of Revlimid (lenalidomide) in this study are... (for more see dbGaP study page.)